Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4816—Wall or shell material
  • A61K9/4825—Proteins, e.g. gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A61K31/355—Tocopherols, e.g. vitamin E
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/60—Salicylic acid; Derivatives thereof
  • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
  • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
  • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/88—Liliopsida (monocotyledons)
  • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
  • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4816—Wall or shell material
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/10—Laxatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds

Definitions

• the present invention relates to enteric preparations, More particularly, the invention relates to enteric solid dosage forms made using a gel mass comprising a film- forming, water-soluble polymer, an acid-insoluble polymer, and, optionally, other ingredients such as plasticizers, colors, and flavors.
• the invention further provides a direct method for manufacturing enteric preparations without need for coating.
• enteric dosage forms are well known to skilled personnel. Such dosage forms have been explained and reviewed in reference works, e.g., in Remington's Pharmaceutical Sciences, 18 th edition, Mack Publishing Co., Easton, PA (1990). Enteric dosage forms are desirable, either to protect the content of the dosage form from the gastric conditions or to protect the gastric tissue from an irritant material contained in the enteric dosage form. A further use for enteric dosages is prevention of a lasting, unacceptable mouth odor resulting from ingestion of substances like garlic or fish oil. Enteric dosage forms are also used to provide slow or delayed release of a substance. To fulfill the compendium definition requirement for enteric or gastro-resistant preparations, these preparations have to pass specific compendia tests.
• enteric or gastro-resistant property is obtained only if the enteric dosage form does not dissolve or disintegrate in gastric acidity for a specified amount of time (usually two hours in 0.1 N hydrochloric acid at 37 C). Further, the enteric dosage forms must release their contents in simulated intestinal environments (e.g., in buffers of pH values at about 6.8 within certain time periods). Detailed evaluation techniques are described in national and international pharmacopoeia such as United States Pharmacopoeia.
• enteric dosage forms The majority, if not all, of the enteric dosage forms currently in use are produced by a film-coating process, where a thin film layer of acid-insoluble (enteric) polymer is accumulated on the surface of an pre-manufactured dosage form. Dosage forms coated in this manner have been mainly tablets and, to a lesser extent, hard or soft capsules.
• the enteric coating method involves spraying of an aqueous or organic solution or a suspension of enteric polymers onto tumbling or moving tablets or capsules, accompanied by drying using hot air.
• Enteric dosage forms made by coating suffer from various process-related problems and defects that affect their performance or appearance. For example, "orange peel" surface formation, also known as surface roughness, mottling, or lack of surface homogeneity may result. And more seriously, coat integrity failure may occur, such as in cases of cracking or flaking off of the coating. All coatings present inherent problems, including possible uneven distribution of the coating ingredients, which can easily happen under the multivariate coating process.
• the foregoing problems of enteric coatings are shared by all enteric dosage forms such as tablets and capsules. However, the problems faced during coating of capsules are even more critical, due to the delicate and heat sensitive nature of the soft elastic capsule shell. Both hard and soft capsules can easily undergo agglomeration and distortion due to the heat-sensitive shell composition.
• enteric coating for soft capsules is the loss of the normally shiny and clear appearance of capsule gelatin shells.
• the elegant, clear gelatin shell has been a significant reason for soft capsule popularity and acceptance.
• most accepted aqueous enteric polymer preparations result in opaque capsules.
• enteric soft gelatin capsules While different attempts have been tried to improve the manufacture of enteric soft gelatin capsules via coating, the inherent disadvantages in the coating process amplify the necessity for a better way of manufacturing enteric soft capsules, ideally, without coating. Enteric coatings (both sub-coating and over-coatings) and enteric polymers are discussed or suggested generally in U.S. Pat. Nos. 4,518,433, 4,816,259, and 5,330,759. None of these references, however, teach or suggest the invention as set forth herein.
• a second aspect of this invention is a filled enteric soft capsule that does not require enteric coating or cross-linking to gain its enteric character.
• fill materials can be hydrophilic or hydrophobic in nature. Fill materials can also be liquid, solid or a combination thereof.
• a third aspect of this invention is a soft capsule enteric shell composition that contains a film-forming polymer, an acid- insoluble polymer, and, optionally, plasticizers, colors, and/or other conventionally accepted pharmaceutical additives.
• the gel mass composition of the invention avoids significant loss of physical strength or viscosity of the film-forming polymer.
• a fourth aspect of this invention is a process of preparing a gel mass from which the enteric capsule shell is made. According to the process of this aspect of the invention, an alkali is used at a level allowing dissolution of the acid-insoluble polymer without negatively affecting the film-forming polymer integrity, its physical strength, or its viscosity.
• a fifth aspect of this invention is a process of manufacturing filled enteric soft capsules using cast gel mass and a rotary die encapsulation machine, such as that disclosed in U.S. Patents 5,146,730 and 5,459,983, incorporated herein by reference and commonly owned by the assignee of this application.
• a sixth aspect of this invention is production of clear enteric soft capsules.
• a seventh aspect of this invention is the production of transparent, yet colored, enteric soft capsules.
• An eighth aspect of the invention is the use of the foregoing aspects for delivering food and medicine.
• the gel mass compositions of this invention are further useful to manufacture enteric solid oral dosage forms such as tablets, and hard and soft capsules without the conventional coating technique.
• a preferred method of manufacturing enteric tablets with this invention is to use enrobement techniques and a rotary die as described in US Patent Nos. 6,482,516 and 5,459,983, and 5,146,730, all fully incorporated herein by reference.
• Gel compositions of this invention are also useful to make clear or opaque hard capsules using regular equipment known in the art.
• the present invention relates to a gel mass composition
• a gel mass composition comprising a film-forming, water-soluble polymer, an acid-insoluble polymer, and, optionally, at least one plasticizer, an optional coloring agent and an aqueous solvent.
• the gel mass is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating.
• the film-forming, water-soluble polymer can be of proteinaeous nature, such as gelatin.
• the gelatin is extracted from animal bones or skins, and has about 100 to about 250 blooms.
• the film- forming, water-soluble polymer can be of carbohydrate nature such as hydroxypropyl methylcellulose or methyl cellulose.
• the acid- insoluble polymer can also be selected from the group consisting of acrylic and methacrylic acid copolymers, cellulose acetate esters such as phthalate, butyrate, hydroxypropyl methyl cellulose phthalate, and salts thereof.
• the shell composition of the invention can contain at least one plasticizer selected from the from the group consisting of sorbitol, glycerol, polyethlene glycol, poly-alcohols with 3 to 6 carbon atoms, citric acid, citric acid esters such as triethyl citrate, and combinations thereof.
• the solvent used can be water or aqueous solution of alkalis, such as ammonia, sodium hydroxide, potassium hydroxide, ethylene diamine, hydroxylamine, tri-ethanol amine, or hydroalcoholic solutions of the same.
• the alkali can adjusted such that the final pH of the gel mass is less than or equal to about 9.0 pH units. In another embodiment, the alkali is adjusted such that the pH does not exceed 8.5. hi yet another embodiment, the alkali is adjusted such that the pH does not exceed 8.0.
• the alkali can be a volatile alkali such as ammonia or ethylene-diamine.
• compositions of the invention are characterized by a consistency compatible with desirable process handling, such as rotary die processing for capsule formation.
• desirable process handling such as rotary die processing for capsule formation.
• the compositions of the invention avoid undue degradation of the film-forming, water-soluble polymer by avoiding excessively alkaline conditions during processing.
• the invention also relates to a process of manufacturing a shell composition into soft capsules.
• the process includes preparing a solution comprising a film-forming, water- soluble polymer and an acid-insoluble polymer and mixing with appropriate plasticizers to form a gel mass; casting gel mass into films or ribbons using heat-controlled drums or surfaces; and manufacturing a soft capsule using rotary die technology.
• the thickness of the films or ribbons is from about 0.015 inches to about 0.050 inches. In one embodiment, the thickness is about 0.020 inches.
• the moisture content of the shell composition can be from about 2% to about 10%.
• the moisture content can also be from about 4% to about 8%.
• the moisture content of particular embodiments is about 8%.
• the invention also relates to an enteric gel composition having an enteric polymer to film-former polymer ratio of from about 20:80 to about 45:55.
• the invention also relates to an enteric gel composition having a plasticizer to polymer ratio from about 10% to about 50% of the polymer weight. In one embodiment, the ratio is about 25%.
• Capsules prepared in accordance with the methods of the invention can be used to contain a hydrophilic fill solution or suspension containing polyethylene glycol.
• the fill composition can be a hydrophobic solution or suspension, such as vegetable oils or shortening, or waxes, or combinations thereof.
• the present invention provides enteric gel mass compositions that do not require cross-linking to achieve the desired enteric properties.
• Cross-linking treatments can cause potential toxicity concerns, and can lead to an uncontrolled process which lead to a product subject to deterioration over time. Further, such cross-linking adds an additional step to the manufacturing process.
• This invention discloses a composition, process of manufacture and use of enteric oral solid dosage forms, namely tablets, and hard and soft capsules that do not require a coating or cross-linking in order to possess enteric properties.
• the gel mass of this invention can be made by mixing a film-forming polymer with an acid-insoluble polymer, and plasticizing materials to forai a homogeneous mixture, in presence of a solvent.
• the invention provides an acid-insoluble polymer within the film-former mass that renders the total mass an enteric material, at relatively low concentrations of the acid-insoluble polymer (from about 8% to about 20% of the total wet gel mass) and without the need of excessive amounts of alkali, thus avoiding degradation or weakening of the film- forming polymer.
• the ratio of acid-insoluble polymer to film-forming polymer is greater than about 1:4.
• Films made by casting the final gel mass do not dissolve or disintegrate in acids, such as 0.1 M hydrochloric acid, despite the fact that the majority of shell ingredients (more than 50%) normally dissolve in, or are miscible with, acids. Enteric films made using the disclosed compositions remain substantially intact in hydrochloric acid. Further, enteric films of this invention reduce migration of small molecules such as methylene blue through them in acidic environments, h another embodiment, the final gel mass provides films of increased strength without substantially compromising film elasticity. Moreover, casting films according to the invention are able to be sealed at normal temperature range typically used for making softgel capsules (from about 80° F to about 105° F) or can be used to surround or enrobe tablets to make them enteric. The gel masses can also be cast around pins to form two-piece hard capsules as illustrated in Remington's Pharmaceutical Sciences, 18 th edition, published by Mack Publishing Co., Easton, PA (1990)
• film-former polymers that are useful in this invention can be of natural origin, preferably gelatin, or of synthetic nature such as hydroxypropyl methyl cellulose.
• acid-insoluble polymers are cellulose acetate phthalate (CAP), cellulose acetate butyrate, hydroxypropyl methyl cellulose phthalate, algenic acid salts such as sodium or potassium alginate, shellac, acrylic acid-methacrylic acid copolymers (available under the trade name of EUDRAGIT (Rohm America Inc., Piscataway, NJ) as powder or 30% aqueous dispersion, or under the trade name of EASTACRYL as 30% dispersion (Eastman Chemical Company, Kingsport, TN), and sodium alginate.
• Acrylic-methacrylic acid copolymers are particularly stable and may be preferred in some embodiments. Acid- insoluble polymers specifications are detailed in the United States Pharmacopoeia.
• Useful plasticizers according to the invention are glycerol, sorbitol, polyethylene glycol, citric acid, citric acid esters, such as tri-ethyl citrate, or combinations thereof.
• the composition ratio between the film-former and the acid-insoluble polymer is adjusted so that the gel mass can be made into soft capsules.
• enteric capsules can be made with an acid- insoluble polymer comprising as little as about 8% of the total content of the wet shell mass, and as high as about 30% of the total wet shell mass.
• the weight ratio range of acid- insoluble polymer/film-former polymer is from about 25% to about 50%. The range can be from about 30% to about 40%.
• enteric gel masses can be made by dissolving the acid-insoluble polymer powder in aqueous solution of an alkali such as ammonia, sodium hydroxide, or potassium hydroxide, or liquid amines such as tri- ethanol amine or ethylene diamine.
• an alkali such as ammonia, sodium hydroxide, or potassium hydroxide, or liquid amines such as tri- ethanol amine or ethylene diamine.
• the amount of alkali is adjusted to give a final pH value of the gel mass less than or equal to about 9.0 pH units. In one embodiment, the final pH does not exceed 8.5.
• Volatile alkalis such as ammonia and ethylene diamine are preferred.
• the film-former can then be wetted by the plasticizer and mixed with the acid- insoluble gel to make a final homogeneous mix in a heat-controlled vessel and can be degassed by using vacuum.
• the enteric gel can be made by using a ready-made aqueous dispersion of the acid-insoluble polymer by adding alkaline materials such as ammonium, sodium, or potassium hydroxides or other alkalis that will cause the acid-insoluble polymer to dissolve, such as triethanol amine or ethylene diamine or a combination thereof.
• alkaline materials such as ammonium, sodium, or potassium hydroxides or other alkalis that will cause the acid-insoluble polymer to dissolve, such as triethanol amine or ethylene diamine or a combination thereof.
• the plasticizer-wetted, film-forming polymer can then be mixed with the solution of the acid-insoluble polymer.
• acid-insoluble polymers in the form of salts of the above- mentioned bases or alkalis can be dissolved directly in water and mixed with the plasticizer-wetted, film-forming polymer.
• the enteric composition of the invention comprising a film-forming polymer (e.g., gelatin or a synthetic polymer) and at least one enteric, acid-insoluble polymer, can be used to contain a fill that is liquid, semi-solid, or solid.
• a film-forming polymer e.g., gelatin or a synthetic polymer
• enteric, acid-insoluble polymer e.g., a fill that is liquid, semi-solid, or solid.
• a gel mass was made according to the formula below.
• the acid-insoluble polymer
• EUDRAGIT L 100 was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
• the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60°C.
• Example 1 Gel mass of Example 1 was cast as a ribbon with 0.03" thickness on a cold drum (10° C to 13° C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration testing as per the requirement of current USP.
• Example 3 Enteric soft capsules with oil-based fill
• Example 1 Gel mass of Example 1 was cast into a ribbon with 0.03" thickness on a cold drum (10° C to 13° C). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
• Example 4 Enteric soft capsules with oil-based fill Gel mass of Example 1 was casted as a ribbon with 0.03" thickness on a cold drum
• This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 20 oblong die.
• the capsules were dried and subjected for dissolution / disintegration analysis as per the requirements of current USP.
• Example 5 Enteric soft capsules with oil-based fill containing a biphosphonate
• Example 1 Hydrogenated soybean oil was melted at 65 °C with soybean oil and to this mixture, Alendronate sodium was added and mixed using homogenizer at 1000 rpm for 5 minutes. Gel mass of Example 1 was cast as a ribbon with 0.03" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of above mentioned fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
• Example 6 Enteric soft capsules with hydrophilic fill Alendronate Sodium 1.26%
• Example 1 Polyethylene glycol was melted at 55°C with polyethylene glycol (400) and to this mixture, Alendronate sodium was added and mixed using a homogenizer at 1000 rpm for 5 minutes. Gel mass of Example 1 was cast into a ribbon with 0.03" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of above mentioned fill using 7.5 oval die. Capsules were dried and subjected to dissolution/disintegration analysis as per the requirements of current USP.
• Example 7 Enteric soft capsules with a hydrophilic/hydrophobic fill
• Alendronate sodium was dissolved in water (part 1). Hydrogenated soybean oil and vegetable shortening was melted at 65°C with soybean oil (part 2). Part 1 and 2 is mixed and passed five times through the MICROFLUIDIZER ® at 10,000 psi. Gel mass of example 1 was casted as a ribbon with 0.03" thickness on a cold drum
• a gel mass was made according to the formula below.
• the acid-insoluble polymer, EUDRAGIT L 100 was dissolved in the water- alkali vehicle, triethyl citrate was then added.
• the film- forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol. And added to the enteric polymer solution, mixed for 2 hours and was kept overnight at 60°C.
• Example 9 Enteric soft capsules with oil-based fill
• Example 6 Gel mass of Example 6 was cast into a ribbon with 0.03" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 10 Enteric soft capsules with oil-based fill
• Gel mass of example 6 was cast into a ribbon with 0.025" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 11 Enteric soft capsules with oil-based fill Gel mass of example 6 was cast into a ribbon with 0.020" thickness on a cold drum
• Example 12 Enteric soft capsules with oil-based fill
• Gel mass of example 6 was cast into a ribbon with 0.015" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• a gel mass was made according to the formula below.
• the acid-insoluble polymer, EUDRAGIT L 100 was dissolved in the water-alkali vehicle, triethyl citrate was then added.
• the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol. And added to the enteric polymer solution, mixed for 2 hours and was kept overnight at 60°C.
• Example 14 Enteric soft capsules with oil-based fill
• Example 13 Gel mass of Example 13 was cast into a ribbon with 0.050" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 15 Enteric soft capsules with oil-based fill
• Example 13 Gel mass of Example 13 was cast into a ribbon with 0.045" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 16 Enteric soft capsules with oil-based fill
• Gel mass of example 13 was cast into a ribbon with 0.040" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 17 Enteric soft capsules with oil-based fill
• Gel mass of Example 13 was cast into a ribbon with 0.035" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution disintegration analysis as per the requirement of current USP.
• Example 18 Enteric soft capsules with oil-based fill
• Example 13 Gel mass of Example 13 was cast into a ribbon with 0.030" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 19 Enteric soft capsules with oil-based fill
• Example 13 Gel mass of Example 13 was cast into a ribbon with 0.025" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 20 Enteric soft capsules with oil-based fill Gel mass of Example 13 was cast into a ribbon with 0.020" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried a d subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 21 Enteric soft capsules with oil-based fill
• Example 13 Gel mass of Example 13 was cast into a ribbon with 0.015" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 22 Enteric soft capsules with oil-based fill containing garlic
• Garlic extract was mixed with soybean oil at 200 rpm using a propeller mixer.
• Example 13 Gel mass of Example 13 was cast into a ribbon with 0.03" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of above-mentioned garlic fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
• Example 23 Enteric soft capsules with oil-based fill containing Omeprazole
• Vitamin E TPGS and CREMOPHOR RH40 were melted with medium chain triglyceride at 40°C. Omeprazole was added to the above mixture and mixed well.
• Example 13 Gel mass of Example 13 was casted as a ribbon with 0.03" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of above mentioned Omeprazole fill using 3 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
• Example 24 Enteric gel mass A gel mass was made according to the formula below.
• the acid-insoluble polymer The acid-insoluble polymer,
• EUDRAGIT L 100 was dissolved in the water- alkali vehicle, triethyl citrate was then added.
• the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol. And added to the enteric polymer solution, mixed for 2 hours and was kept overnight at 60°C.
• Example 25 Enteric soft capsules with oil-based fill
• Example 24 Gel mass of Example 24 was cast into a ribbon with 0.030" thickness on a cold drum (10°C to 13°C). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
• Example 26 Hydrophilic enteric soft capsules containing Bisacodyl
• Acetic acid was added to polyethylene glycol (400) and mixed well.
• Bisacodyl was added to the polyethylene glycol/acetic acid mixture and mixed using a propeller mixture at 60°C for 30 minutes (till completely dissolved).
• Example 23 Gel mass of Example 23 was cast into a ribbon with 0.03" thickness on a cold drum (10°C to 13°C). This ribbon was utilized for encapsulation of above-mentioned Bisacodyl fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
• Vegetable shortening, hydrogenated vegetable oil, and beeswax were melted with soybean oil at 65°C.
• Bisacodyl was added and mixed using a propeller mixer and the mix is cooled back to room temperature.
• Example 24 Gel mass of Example 24 was cast into a ribbon with 0.03" thickness on a cold drum (10 to 13°C). This ribbon was utilized for encapsulation of above-mentioned Bisacodyl fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
• Example 28 Methylene blue permeation studies using dialysis chamber Methylene blue (water soluble dye) was dissolved in 0.1 N HC1 placed on one side of the chamber and plain 0.1 N HC1 on the other side of the chamber separated using enteric gel mass according to Example 1. This setup was placed in shaking water bath at 37°C, samples were removed up to 2 hours at periodic time intervals of 10, 20, 30, 45, 60, 90 and 120 minutes.
• the 0.040" ribbon thickness capsules exhibited no swelling and stayed intact in SGF: they dissolved between 30 and 60 minutes in SIF. Thinner ribbons were also used for the same foramla as shown in Table 1.
• Table 1 Example Parameter and Testing Summary
• Example 30 Enteric gel mass containing cellulose acetate phthalate (CAP) and using ammonium hydroxide as the alkali solubilizer
• a gel mass was made according to the formula below.
• the acid-insoluble polymer, (CAP) was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
• the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60°C.
• Example 31 Enteric gel mass containing cellulose acetate phthalate (CAP) and using sodium hydroxide as the alkali solubilizer A gel mass was made according to the formula below.
• the acid-insoluble polymer CAP
• CAP was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
• the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60°C.
• Cellulose Acetate Phthalate as 30% W/V dispersion
• a gel mass was made according to the formula below.
• the acid-insoluble polymer shellac was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
• the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60°C.
• Example 33 Preparation of enteric aspirin Enteric aspirin tablets were made using the enteric gel mass of Example 24 and a rotary die machine as per the process described in US Patent Nos. 5,459,983, 5,146,730 and 6,482,516.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Biotechnology (AREA)
• Alternative & Traditional Medicine (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Inorganic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Medical Preparation Storing Or Oral Administration Devices (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=32069824

Family Applications (1)

Country Status (14)

Cited By (31)

Families Citing this family (25)

Citations (9)

Family Cites Families (12)

• 2003
  • 2003-06-27 DK DK03742336.5T patent/DK1545475T3/da active
  • 2003-06-27 JP JP2004541451A patent/JP5248739B2/ja not_active Expired - Lifetime
  • 2003-06-27 PT PT141704924T patent/PT2772250T/pt unknown
  • 2003-06-27 EP EP03742336.5A patent/EP1545475B1/en not_active Expired - Lifetime
  • 2003-06-27 AU AU2003299191A patent/AU2003299191A1/en not_active Abandoned
  • 2003-06-27 US US10/529,984 patent/US8685445B2/en active Active
  • 2003-06-27 PT PT37423365T patent/PT1545475E/pt unknown
  • 2003-06-27 HU HUE14170492A patent/HUE031650T2/en unknown
  • 2003-06-27 SI SI200332504A patent/SI2772250T1/sl unknown
  • 2003-06-27 ES ES14170492.4T patent/ES2609059T3/es not_active Expired - Lifetime
  • 2003-06-27 EP EP14170492.4A patent/EP2772250B1/en not_active Expired - Lifetime
  • 2003-06-27 CN CNA038235579A patent/CN1688294A/zh active Pending
  • 2003-06-27 WO PCT/US2003/020579 patent/WO2004030658A1/en not_active Ceased
  • 2003-06-27 DK DK14170492.4T patent/DK2772250T3/en active
  • 2003-06-27 SI SI200332379T patent/SI1545475T1/sl unknown
  • 2003-06-27 MX MXPA05003524A patent/MXPA05003524A/es active IP Right Grant
  • 2003-06-27 CA CA2500663A patent/CA2500663C/en not_active Expired - Lifetime
  • 2003-06-27 ES ES03742336.5T patent/ES2500316T3/es not_active Expired - Lifetime
• 2014
  • 2014-03-28 US US14/228,387 patent/US9433585B2/en not_active Expired - Fee Related
• 2016
  • 2016-11-21 CY CY20161101198T patent/CY1118258T1/el unknown

Patent Citations (10)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events